Table 2 Rectal colonization with resistant Gram-negative bacteria at and after ICU discharge and number of resistance phenotypes (to ceftazidime, tobramycin, colistin, meropenem and ciprofloxacin)
Number of patients colonized with ARGNB at ICU discharge | Number of patients acquiring colonization with ARGNB after ICU discharge | |||||
|---|---|---|---|---|---|---|
SDD (n = 507) | SOD (n = 489) | p value* | SDD (n = 426) | SOD (n = 409) | p value* | |
At least one AR-GNB | ||||||
ICU A | 8/154 (5.2%) | 29/271 (10.7%) | 0.05 | 14/134 (10.4%) | 38/224 (17.0%) | 0.09 |
ICU B | 6/115 (5.2%) | 38/124 (30.6%) | < 0.0001 | 9/95 (9.5%) | 16/96 (16.7%) | 0.14 |
ICU C | 8/238 (3.4%) | 20/94 (21.3%) | < 0.0001 | 18/197 (9.1%) | 10/89 (11.2%) | 0.6 |
All | 22/507 (4.3%) | 87/489 (17.8%) | < 0.0001 | 41/426 (9.6%) | 64/409 (15.6%) | 0.01 |
Different ARGNB | 23 | 97 | < 0.0001 | 66 | 90 | 0.02 |
E.coli | 10 | 46 | 20 | 36 | ||
Enterobacter sp. | 1 | 11 | 8 | 15 | ||
K. pneumoniae | 1 | 9 | 6 | 4 | ||
P. aeruginosa | 3 | 15 | 6 | 15 | ||
other | 8 | 16 | 26 | 20 | ||
Resistance phenotypes | ||||||
Ceftazidime | 9 | 46 | 21 | 27 | ||
Ciprofloxacin | 11 | 40 | 12 | 29 | ||
Tobramycin | 17 | 33 | 23 | 36 | ||
Meropenem | 0 | 3 | 1 | 3 | ||
Colistin | 5 | 10 | 7 | 11 | ||
ESBL | 7 | 60 | 20 | 24 | ||